Participating Faculty

The American Journal of Managed Care

This supplement to contains information on the managementand treatment of attention-deficit/hyperactivity disorder.

Faculty

Oscar G. Bukstein, MD, MPH

Associate Professor of Psychiatry

University of Pittsburgh School of Medicine

Western Psychiatric Institute and Clinic

Pittsburgh, Pennsylvania

Mark A. Stein, PhD

Professor of Psychiatry

Director of HALP Clinic and ADHD Clinical Research

Child and Adolescent Psychiatry

The University of Chicago

Chicago, Illinois

Kenneth W. Steinhoff, MD

Associate Clinical Professor

University of California, Irvine

Child Development Center

Irvine, California

Mark Olfson, MD, MPH

Professor of Clinical Psychiatry

Department of Psychiatry

Columbia University

New York, New York

FACULTY DISCLOSURE

The American Journal of Managed Care

It is policy at to have all faculty who participate in programssponsored by corporate organizations disclose any real or apparent conflicts of interest.

• Oscar G. Bukstein, MD, MPHGrant/Research Support From:McNeil Consumer & Specialty PharmaceuticalsNovum PharmaceuticalsSpeakers' Bureau For:McNeil Consumer & Specialty Pharmaceuticals
• Mark A. Stein, PhD Consultant To/Investigator For:Eli LillyConsultant To/Speakers' Bureau For:McNeil Consumer & SpecialtyPharmaceuticalsNovartis
• Kenneth W. Steinhoff, MD Consultant To/Speaker For/Research From:McNeil Consumer & Specialty Pharmaceuticals Speaker For/Research From/Advisor To:LillyConsultant To/Research From:ScheringResearch From/Speaker For:CephalonNovartisResearch Support From:Celltech
• Mark Olfson, MD, MPH Advisor To/Principal Investigator For:Bristol-Myers SquibbCo-Principal Investigator For:LillyOutcomes Research Consultant To:McNeil Pharmaceuticals

The American Journal of Managed Care

Signed disclosures are on file at the offices of , Jamesburg,New Jersey.

This program is being supported by an educational grant from McNeil Consumer & Specialty Pharmaceuticals .

The contents of this supplement may include information regarding the use of products that may beinconsistent with or outside the approved labeling for these products in the United States.Physicians should note that the use of these products outside current approved labeling is consideredexperimental and are advised to consult prescribing information for these products.

Download PDF: Participating Faculty